Search by Journal

Neurological Therapeutics

Volume 39, Issue 4 / 2022
English Article   Japanese Article
  • Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
Japanese Article The condition of a patient and treatment of the secondary progressive form multiple sclerosis
中原仁*
Neurological Therapeutics 39(4): 429-429, 2022.
Japanese Article Translational research for neuromuscular diseases
Norio MOTOHASHI, Yoshitsugu AOKI
Neurological Therapeutics 39(4): 430-434, 2022.
Japanese Article Stroke prevention based on the Stroke Treatment Guideline 2021
Yoshiaki ITOH
Neurological Therapeutics 39(4): 435-438, 2022.
Japanese Article Reconsideration the molecular pathogenesis of cerebral small vessel disease
Sho KITAHARA, Taisuke KATO, Osamu ONODERA
Neurological Therapeutics 39(4): 439-443, 2022.
Japanese Article Mechanism and treatment for immune-mediated neuropathies
Toshiki FUJIOKA
Neurological Therapeutics 39(4): 444-446, 2022.
Japanese Article Diagnosis and treatment strategies for Alzheimer's disease
下濱俊*
Neurological Therapeutics 39(4): 447-447, 2022.
Japanese Article Personalized medicine based on the pathophysiology of HTLV-1-associated myelopathy
Naoki TAKAO*, Yoshihisa YAMANO*,**
Neurological Therapeutics 39(4): 448-452, 2022.
Japanese Article Clinical practice guideline for rare diseases : with regard to Minds Handbook for clinical practice guideline development 2020
Noriko KOJIMAHARA
Neurological Therapeutics 39(4): 453-457, 2022.
Japanese Article The diagnosis of ESUS starts not a goal
立石洋平*, 辻野彰*
Neurological Therapeutics 39(4): 458-458, 2022.
Japanese Article Symposium 9 clinical practice of the fault fixed form parkinsonism: Clinical practice of the update 2021 non-fixed form parkinsonism, Term of the update 2021 host
織茂智之
Neurological Therapeutics 39(4): 459-459, 2022.
Japanese Article Multiple system atrophy therapeutic development update
Hirohisa WATANABE*, Sayuri SHIMA*, Yasuaki MIZUTANI*, Mizuki ITO*,**, Akihiro UEDA*,***
Neurological Therapeutics 39(4): 460-463, 2022.
Japanese Article 2 progressive supranuclear palsy update
下畑享良*
Neurological Therapeutics 39(4): 464-464, 2022.
Japanese Article Difficulties in the clinical diagnosis of corticobasal degeneration
Yuichi HAYASHI, Takayoshi SHIMOHATA
Neurological Therapeutics 39(4): 465-467, 2022.
Japanese Article Update on dementia with Lewy bodies
Kenji WADA
Neurological Therapeutics 39(4): 468-471, 2022.
Japanese Article Atypical parkinsonism and sleep disturbances
Keisuke SUZUKI
Neurological Therapeutics 39(4): 472-476, 2022.
Japanese Article Progress of the molecular target treatment of 1 late years
戸田達史*
Neurological Therapeutics 39(4): 477-477, 2022.
Japanese Article Advances in treatment of spinal muscular atrophy and presymptomatic diagnosis/treatment
Kayoko SAITO
Neurological Therapeutics 39(4): 478-483, 2022.
Japanese Article The role of genetic counseling and presymptomatic diagnosis in Huntington's disease : Case study in a university hospital
Hyangri CHANG*, Hiroyuki ISHIURA*,**, Tatsushi TODA*,**
Neurological Therapeutics 39(4): 484-488, 2022.
Japanese Article Ethical issues in assisted reproductive technology and prenatal care - Non-invasive prenatal genetic testing and preimplantation genetic testing -
Mikio MIKAMI
Neurological Therapeutics 39(4): 489-494, 2022.
Japanese Article Cancer genomic medicine (precision medicine)
Katsutoshi ODA
Neurological Therapeutics 39(4): 495-499, 2022.
Japanese Article It is the term of the paradigm shift host of the treatment symposium 11 for paradigm shift cerebral infarction acute phase of the treatment for cerebral infarction acute phase
木村和美, 卜部貴夫
Neurological Therapeutics 39(4): 500-500, 2022.
Japanese Article Updates and perspective of intravenous thrombolysis for acute ischemic stroke following the indication expansion using specialized imaging
Masatoshi KOGA*, Manabu INOUE*,**
Neurological Therapeutics 39(4): 501-505, 2022.
Japanese Article Expansion of the indications for mechanical thrombectomy
Kentaro SUZUKI, Kazumi KIMURA
Neurological Therapeutics 39(4): 506-509, 2022.
Japanese Article Antithrombotic therapy in patients with acute and chronic ischemic stroke
Hiroshi YAMAGAMI
Neurological Therapeutics 39(4): 510-513, 2022.
Japanese Article Stem cell therapy for stroke
Akihiko TAGUCHI
Neurological Therapeutics 39(4): 514-516, 2022.
Japanese Article Discovery of drugs targeting post-ischemic inflammation in ischemic stroke
Munehisa SHIMAMURA*,**, Hironori NAKAGAMI**, Tsutomu SASAKI*, Hideki MOCHIZUKI*
Neurological Therapeutics 39(4): 517-521, 2022.
Japanese Article It is the term of the prospects host to new treatment of the prospects rebelliousness neuropathy to new treatment of the rebelliousness neuropathy symposium 12
楠進
Neurological Therapeutics 39(4): 522-522, 2022.
Japanese Article 1 POEMS syndrome
三澤園子*
Neurological Therapeutics 39(4): 523-523, 2022.
Japanese Article The front line of 2 ATTR amyloidosis treatment
関島良樹*
Neurological Therapeutics 39(4): 524-524, 2022.
Japanese Article Trend of 3 CIDP treatment
飯島正博*
Neurological Therapeutics 39(4): 525-525, 2022.
Japanese Article Gene- and nucleic acid-based therapeutics for spinal muscular atrophy
Fumiaki TANAKA
Neurological Therapeutics 39(4): 526-529, 2022.
Japanese Article It is the term of the front line host of the treatment strategy with nucleic acid medicine of the front line neuromuscular disorders of the treatment strategy with nucleic acid medicine of neuromuscular disorders symposium 13
横田隆徳
Neurological Therapeutics 39(4): 530-530, 2022.
Japanese Article 1 Chemistry of Nucleic Acid Medicine
小比賀聡*
Neurological Therapeutics 39(4): 531-531, 2022.
Japanese Article Blood-brain-barrier crossing heteroduplex oligonucleotide
Takanori YOKOTA
Neurological Therapeutics 39(4): 532-534, 2022.
Japanese Article Development of exon 53 skipping drug, viltolarsen, to Duchenne muscular dystrophy
Shin'ichi TAKEDA
Neurological Therapeutics 39(4): 535-538, 2022.
Japanese Article 4 Practice of Nucleic Acid Medicine Treatment for Hereditary Transthyretin Amyloidosis
植田光晴*
Neurological Therapeutics 39(4): 539-539, 2022.
Japanese Article Current status and future of gene therapy for spinal muscular atrophy
高嶋博*
Neurological Therapeutics 39(4): 540-540, 2022.
Japanese Article It is the term of the role host of the cranial nerve physician in the role nerve first aid of the cranial nerve physician in the nerve first aid symposium 14
西山和利
Neurological Therapeutics 39(4): 541-541, 2022.
Japanese Article Neurologists in stroke medicine
Yuko TANAKA
Neurological Therapeutics 39(4): 542-545, 2022.
Japanese Article The role of neurologists in the treatment of older patients with epilepsy
Tomotaka TANAKA
Neurological Therapeutics 39(4): 546-549, 2022.
Japanese Article Achievement (including autoimmune encephalitis and the unidentified status epilepticus) of the cranial nerve physician in 3 inflammatory diseases of brain practice
飯塚高浩*
Neurological Therapeutics 39(4): 550-550, 2022.
Japanese Article Neuromuscular junction disease in settings of 4 nerve first aid
村井弘之*
Neurological Therapeutics 39(4): 551-551, 2022.
Japanese Article The condition of a patient, the latest knowledge of 5 ICUAW
今井富裕*
Neurological Therapeutics 39(4): 552-552, 2022.
Japanese Article Symposium 15 : Sleep Disorders in Neurological Diseases and Their Countermeasures Sleep Disturbances in Neurological Disorders and Their Countermeasures word of the moderator
平田幸一
Neurological Therapeutics 39(4): 553-553, 2022.
Japanese Article Clinical practice of stroke and sleep-related disorders
Tomoyuki MIYAMOTO*, Yasuhisa AKAIWA*, Masayuki MIYAMOTO**
Neurological Therapeutics 39(4): 554-557, 2022.
Japanese Article For adequacy of 2 Restless legs syndrome (RLS) treatment
井上雄一*
Neurological Therapeutics 39(4): 558-558, 2022.
Japanese Article Sleep disturbances in Parkinson disease : Focusing on REM sleep behavior disorder
Keisuke SUZUKI
Neurological Therapeutics 39(4): 559-563, 2022.
Japanese Article Migraine and sleep
Takao TAKESHIMA
Neurological Therapeutics 39(4): 564-568, 2022.
Japanese Article 5 Sleep disturbances in neurodegenerative diseases
岡靖哲*
Neurological Therapeutics 39(4): 569-569, 2022.
Japanese Article It is the term of the front line host of the disease modifier development of front line dementia of the disease modifier development of dementia symposium 16
冨本秀和
Neurological Therapeutics 39(4): 570-570, 2022.
Japanese Article 1 Clinical development of aducanumab for early Alzheimer's disease
戸田康夫*
Neurological Therapeutics 39(4): 571-571, 2022.
Japanese Article Pathophysiological biomarker-based clinical development of lecanemab (BAN2401), anti-Aβ protofibril antibody
Akihiko KOYAMA
Neurological Therapeutics 39(4): 572-574, 2022.
Japanese Article 3 Clinical Development and Biomarkers of Donanemab: Changes in Amyloid Plaque Volume in a Phase II Study
佐藤祥一郎*, Sergey Shcherbinin**, Scott W Andersen**, Cynthia Duggan Evans**, Albert Lo**, Ming Lu***, Michael Navitsky***, Emily C Collins**,***, John R Sims**, Dawn A Brooks**, Mark A Mintun**,***
Neurological Therapeutics 39(4): 575-575, 2022.
Japanese Article J-TRC : A trial ready cohort for preclinical and prodromal stage Alzheimer disease
Yoshiki NIIMI
Neurological Therapeutics 39(4): 576-580, 2022.
Japanese Article It is the term of the new treatment strategy host of new treatment strategy Parkinson disease of Parkinson disease symposium 17
服部信孝, 高橋一司
Neurological Therapeutics 39(4): 581-581, 2022.
Japanese Article Essentials of pharmacotherapy of early-stage Parkinson disease
Morinobu SEKI
Neurological Therapeutics 39(4): 582-585, 2022.
Japanese Article Update of pharmacotherapy in advanced Parkinson disease
Tetsuya MAEDA
Neurological Therapeutics 39(4): 586-588, 2022.
Japanese Article Therapeutic strategies using deep brain stimulation and levodopa-carbidopa intestinal gel therapy
Keita MATSUURA
Neurological Therapeutics 39(4): 589-594, 2022.
Japanese Article Treatment of the near future when 4 wearable results
大山彦光*, 波田野琢*, 服部信孝*
Neurological Therapeutics 39(4): 595-595, 2022.
Japanese Article It is the term of the video diagnosis topics host of the video diagnosis topics neurodegenerative disease of the neurodegenerative disease symposium 18
鈴木正彦, 渡辺宏久
Neurological Therapeutics 39(4): 596-596, 2022.
Japanese Article The latest information of 1 amyloid PET
石井賢二*
Neurological Therapeutics 39(4): 597-597, 2022.
Japanese Article Tau PET imaging from the basics to the state-of-the-art
Hitoshi SHIMADA
Neurological Therapeutics 39(4): 598-602, 2022.
Japanese Article Connectome analysis of 3 Parkinson's disease spectrum
花川隆*
Neurological Therapeutics 39(4): 603-603, 2022.
Japanese Article 7 tesla ultra-high field magnetic resonance imaging (MRI) of the brain
Masaki FUKUNAGA
Neurological Therapeutics 39(4): 604-607, 2022.
Japanese Article Diagnosis and elucidation of Parkinson related disorders using common medical devices
Mizuki ITO*,**, Akihiro UEDA*, Sayuri SHIMA*, Yasuaki MIZUTANI*, Ryunosuke NAGAO*, Toshiki MAEDA*, Fumihiko BANNO*, Hirohisa WATANABE*
Neurological Therapeutics 39(4): 608-611, 2022.
Japanese Article It is the term of the front line host of the antibody medicine development of the front line rebelliousness migraine headache of the antibody medicine development of the rebelliousness migraine headache symposium 19
竹島多賀夫, 辰元宗人
Neurological Therapeutics 39(4): 612-612, 2022.
Japanese Article Definition of refractory migraine and existing migraine prophylaxis
Shoji KIKUI, Takao TAKESHIMA
Neurological Therapeutics 39(4): 613-619, 2022.
Japanese Article CGRP actions relevant to migraine pathogenesis
Mamoru SHIBATA
Neurological Therapeutics 39(4): 620-624, 2022.
Japanese Article 3 Clinical Trial Results of Galcanezumab, a New Treatment Option to Prevent Migraine Attacks
中村智実*
Neurological Therapeutics 39(4): 625-625, 2022.
Japanese Article Efficacy and safety of erenumab in migraine patients
Ryuji YOSHIDA*, Yotaro NUMACHI*, Miki HASEBE**
Neurological Therapeutics 39(4): 626-631, 2022.
Japanese Article Therapeutic results and safety of fremanezumab in patients with chronic migraine
Nobuyuki KOGA*, Miki ISHIDA**
Neurological Therapeutics 39(4): 632-638, 2022.
Japanese Article It is the term of the how to use how to use new antiepileptic drug - update 2021 new antiepileptic drug update 2021 host symposium 20
松本理器
Neurological Therapeutics 39(4): 639-640, 2022.
Japanese Article Pharmacodynamics of antiseizure drugs on behavioural adverse effect
Motohiro OKADA
Neurological Therapeutics 39(4): 641-645, 2022.
Japanese Article How to manage acute symptomatic seizures and status epilepticus
Hajime YOSHIMURA
Neurological Therapeutics 39(4): 646-649, 2022.
Japanese Article How to use newer antiseizure medications in the daily clinical practice
Taira UEHARA
Neurological Therapeutics 39(4): 650-653, 2022.
Japanese Article The management at 4 initial attacks: Including the positioning of the new antiepileptic drug
井内盛遠*
Neurological Therapeutics 39(4): 654-654, 2022.
Japanese Article About the effectiveness of the levetiracetam Perampanel combination therapy in the convulsive seizure control during 5 awakening poorness operations
本村和也*, 齋藤竜太*
Neurological Therapeutics 39(4): 655-655, 2022.
Japanese Article It is the term of the front line host of the medical therapy for the front line myasthenia gravis of the medical therapy for the myasthenia gravis symposium 21
鈴木重明
Neurological Therapeutics 39(4): 656-656, 2022.
Japanese Article 1 myasthenia gravis/Lambert Eton myasthenic syndrome practice guideline 2021
槍沢公明*
Neurological Therapeutics 39(4): 657-657, 2022.
Japanese Article Myasthenia gravis occurred as immune-related adverse event
Shigeaki SUZUKI
Neurological Therapeutics 39(4): 658-661, 2022.
Japanese Article Treatment with molecular target medicine for 3 myasthenia gravis
鵜沢顕之*
Neurological Therapeutics 39(4): 662-662, 2022.
Japanese Article Because we do not impair the quality of life (quality of life) of patients with 4 myasthenia gravis
長根百合子*
Neurological Therapeutics 39(4): 663-663, 2022.
Japanese Article It is area inclusion care of area inclusion care dementia of dementia medical staff symposium 1: Term of the host
粟田主一, 新堂晃大
Neurological Therapeutics 39(4): 664-664, 2022.
Japanese Article Establishing the community-based integrated care system for dementia in cooperation with local governments
Aki NAKANISHI
Neurological Therapeutics 39(4): 665-669, 2022.
Japanese Article Dementia cafe and community-based integrated care
Hajime TAKECHI
Neurological Therapeutics 39(4): 670-674, 2022.
Japanese Article Team Orange : The provision of early life support for people with dementia and their families
Masaki SHINOHARA
Neurological Therapeutics 39(4): 675-679, 2022.
Japanese Article An approach to early diagnosis of dementia from the results of outreach-type screening
Sumie KAWAGITA
Neurological Therapeutics 39(4): 680-683, 2022.
Japanese Article The role of 5 dementia nursing authorization nurses and the future prospects
後藤裕子*
Neurological Therapeutics 39(4): 684-684, 2022.
Japanese Article Term of the host thinking about fall, fall ... former stick which does not fall down of the nervous disease medical staff symposium 2 at old age to think about fall, fall ... former stick which does not fall down of the nervous disease at old age
内藤寛
Neurological Therapeutics 39(4): 685-685, 2022.
Japanese Article Overview of features and prevention of falls in older patients with neurological disorders
Ikuko AIBA
Neurological Therapeutics 39(4): 686-689, 2022.
Japanese Article 2 "statement about the fall in the nursing facility" and evidence about the fall
楽木宏実*
Neurological Therapeutics 39(4): 690-690, 2022.
Japanese Article Fall risk assessment and prevention in older adults with dementia in hospitals and geriatric institutions
Mizue SUZUKI
Neurological Therapeutics 39(4): 691-695, 2022.
Japanese Article Nutritional intervention for prevention of falls in older adults with neurological diseases
Sahoko TAKAGI
Neurological Therapeutics 39(4): 696-700, 2022.
Japanese Article Rehabilitation of the fall prevention for patients with 5 advanced age nervous disease
松田直美*, 饗場郁子**
Neurological Therapeutics 39(4): 701-701, 2022.
Japanese Article It is the term of the rehabilitation front line host of the rehabilitation front line nervous disease of the nervous disease medical staff symposium 3
安保雅博, 前島伸一郎
Neurological Therapeutics 39(4): 702-702, 2022.
Japanese Article Neurological disorders and botulinum toxin therapy
Asako TAMURA
Neurological Therapeutics 39(4): 703-705, 2022.
Japanese Article Neurorehabilitation ; the application of noninvasive brain stimulation
Tomoo MANO
Neurological Therapeutics 39(4): 706-710, 2022.
Japanese Article Robotic rehabilitation up to date
Mitsuhiro OCHI
Neurological Therapeutics 39(4): 711-714, 2022.
Japanese Article The rehabilitation front line of 4 dementia
大沢愛子*, 前島伸一郎**
Neurological Therapeutics 39(4): 715-715, 2022.
Japanese Article Stimulation therapy for dysphagia of 5 nervous disease
百崎良*
Neurological Therapeutics 39(4): 716-716, 2022.
Japanese Article An optimal scale for predicting gait independence in patients with acute cerebellar infarction
Shohei ITO*, Seiya TANAKA**, Keisuke SUZUKI**
Neurological Therapeutics 39(4): 717-722, 2022.
Japanese Article A case of dementia with rejective attitude successfully treated with music therapy
Noriko WATANABE*, Hitomi SOMA*, Ayaka YOSHINO**, Makiko WADA***, Toshiki FUJIOKA****
Neurological Therapeutics 39(4): 723-726, 2022.
Japanese Article A case of calcified cerebral emboli during hemodialysis
Saro KOBAYASHI*,**, Kentaro IIZUKA*,**, Hidehiro TAKEKAWA*,**,***, Keisuke SUZUKI*
Neurological Therapeutics 39(4): 727-730, 2022.
Japanese Article Cases of anti-aquaporin4 antibody-positive neuromyelitis optica spectrum disorder treated with eculizumab initiated immediately after acute treatment
Kimihiko KANEKO*, Yasuhiro NAMIOKA*, Ayane OHYAMA*, Yoshiki TAKAI*, Noriko HIMORI**, Toru NAKAZAWA**, Tatsuro MISU*, Masashi AOKI*
Neurological Therapeutics 39(4): 731-735, 2022.
▲